AGC Biologics, a CDMO expert, will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.’s Yokohama Technical Center, marking the latest step in the global expansion of the company’s Global Cell and Gene Technologies Division.

The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across all markets, with cell therapy manufacturing now available on three continents (Milan, Italy; Longmont, Colorado, U.S.; Yokohama, Japan).

The Yokohama location will provide process transfer and manufacturing services for pre-clinical and clinical trials to serve an expanding global cell therapy market. Its core technologies include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and CAR-T cell therapies. The AGC Biologics Cell and Gene Technology Center of Excellence in Milan will support and enable the successful ramp up of operations in the new Yokohama site.

Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics, said, “Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy.”

Jun Takami, Senior Vice President and General Manager, Japan Region and Yokohama Facility, remarked, “As part of this next major phase for cell therapy in the region, our Yokohama team is ready to support partners in accelerating drug development timelines while maintaining the highest quality standards in the industry.”